Tirzepatide vs NA-Semax Amidate
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →NA-Semax Amidate
NA-Semax Amidate (N-Acetyl Semax Amidate) is a modified version of Semax with enhanced stability and potency. Also known as NASA, it provides stronger and longer-lasting nootropic effects than standard Semax.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | NA-Semax Amidate |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | Maintains Semax's core actions on BDNF, NGF, and monoamine systems with improved pharmacokinetics. The modifications enhance CNS penetration and extend duration of action. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Intranasal: 100-600mcg 1-2 times daily. Start with lower doses as it's more potent than standard Semax. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Intranasal spray is most common. Can be used sublingually. More stable than standard Semax in solution. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | May cause irritability, hair shedding (rare), or overstimulation at high doses. Generally well-tolerated. |
| Best For |